Evaluating the Effect of Digoxin and Ursodeoxycholic Acid in Patients With Rheumatoid Arthritis

Tanta University90 enrolled

Overview

The purpose of this study is to investigate the potential therapeutic effects of the cardiac glycoside digoxin and the secondary bile acid ursodeoxycholic acid (UDCA) on synovial inflammation and disease activity when administered as add-on treatments to the current DMARDs treatments for rheumatoid arthritis patients with variant disease activity.

This study is a randomized, open-labeled, controlled prospective study to evaluate the potential therapeutic effects of the cardiac glycoside digoxin and the secondary bile acid ursodeoxycholic acid (UDCA) on synovial inflammation and disease activity when administered as add-on treatments to the current DMARDs treatments for rheumatoid arthritis patients with variant disease activity. The study population will be rheumatoid arthritis patients attending the Physical Medicine, Rheumatology and Rehabilitation Department at Menoufia University Hospital, Menoufia, Egypt. A total of 90 rheumatoid arthritis patients who will meet the inclusion criteria will be enrolled in this study. The 90 participants will be divided into 30 rheumatoid arthritis patients who will receive placebo + the current DMARDs treatments of rheumatoid arthritis for 24 weeks and serve as the control group, 30 rheumatoid arthritis patients who will receive DMARDs + digoxin 25 mg every other day for 24 weeks and the last 30 rheumatoid arthritis patients who will receive DMARDs + ursodeoxycholic acid (UDCA) 500 mg/day for 24 weeks. Clinical Examinations and laboratory parameters will be performed and measured at the beginning of the study, 12 weeks and 24 weeks after randomization to evaluate the efficacy of digoxin and UDCA in the treatment of rheumatoid arthritis.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Rheumatoid Arthritis

Interventions

PlaceboDRUG

Placebo will be administered to the control group for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.

Digoxin 0.25 mgDRUG

All subjects will receive digoxin administered at 0.25 mg every other day for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.

Ursodeoxycholic acid (UDCA) 500 mgDRUG

All subjects will receive Ursodeoxycholic acid (UDCA) administered at 500 mg/day for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosed with rheumatoid arthritis according to the ACR/EULAR 2010 criteria. * Having active rheumatoid arthritis disease activity (the 28-joint disease activity score \[DAS28\] according to the CRP formula \> 2.6). * Aged between 18 and 80 years. * With clear consciousness and able to cooperate with this study. * Personal willingness and ability to comply with the study follow-up schedule and other requirements of the study protocol. * Both male and female will be included * All patients receiving non-biological drugs will be also included. * Sign an informed consent for the clinical study. Exclusion Criteria: * Pregnant or planning to be pregnant and breast-feeding women * Patients suffering from any chronic diseases * Patients with other autoimmune diseases, such as systemic lupus erythematosus, Sjogren's syndrome and mixed connective tissue disease. * Patients who have a diagnosis of any other inflammatory arthritis (e.g., psoriatic arthritis or ankylosing spondylitis). * Patients with a history of, or suspected, demyelinating disease of the central nervous system (e.g. multiple sclerosis or optic neuritis). * Patients with a current or recent history of severe, progressive, and/or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, or cerebral disease. * Patients treated with biological therapy such as TNF-α or IL-1β antagonists. * Patients with infectious or inflammatory diseases, endocrine disorders, any past or current psychiatric or neurological diseases. * Patients with cardiovascular diseases such as arrhythmias and acute myocardial infarction. * Patients with electrolyte disturbances (such as hypokalemia, hypomagnesemia, and hypercalcemia) could potentially elevate the risk of digoxin toxicity. * Patients with clinically significant hepatic and renal dysfunction or impairment. * Alcohol abuse * Patients with evidence of viral (HBV or HCV), autoimmune hepatitis, and decompensated liver disease. * Patients with cancer currently diagnosed or in medical history, if no recovery was achieved. * Patients who are allergic to digoxin or Ursodeoxycholic acid (UDCA) * Patients who are unconscious and unable to complete the study. * Patients with acute inflammation of the gall bladder or the biliary tract, frequent episodes of biliary colic, and impaired contractility of the gall bladder, will be excluded. * Patients with cholestasis, primary biliary cirrhosis, or biliary obstruction will also be excluded. * Patients who have received an organ transplant.

Locations (1)

Menoufia University Hospital

Shibīn al Kawm, Egypt

Outcomes

Primary Outcomes

Changes from Baseline in Clinical Disease Activity Index (CDAI) Score

To evaluate the effect of the use of digoxin and UDCA as an add-on therapy in patients with rheumatoid arthritis by evaluating the change from baseline in the clinical findings as measured by Clinical Disease Activity Index (CDAI) scores. A lower CDAI score from Baseline would mean improvement in disease activity and an increase in CDAI score from Baseline would mean an increase in disease activity or a worsening in disease activity. Scores: 0.0-2.8 = Range for Remission; 2.9-10.0 = Range for Low disease activity; 10.1-22.0 Range for Moderate disease activity; 22.1-76 Range for High disease activity. Total range is from 0-100, with the high scores representing high disease activity.

Time frame: Baseline, after 12 weeks, after 24 weeks

Changes in C-Reactive Protein (CRP) Values and Erythrocyte Sedimentation Rates (ESR)

C- reactive Protein (CRP) values and Erythrocyte Sedimentation Rate (ESR) will be made at baseline and after 12 as well as 24 weeks to determine the number of patients whose test result improved or worsened CRP value (normal range \<1.0 mg/dl). ESR (normal range 0-28 mm/hr) . If the value is increased, the disease activity worsened. If the value is reduced the disease activity is improved.

Time frame: Baseline, after 12 weeks, after 24 weeks

Secondary Outcomes

Changes from baseline Measurement of IL-17A and HIF-1α at 12 and 24 weeks

Serum IL-17A and HIF-1α levels will be measured by means of the human enzyme-linked immunosorbent assay (ELISA) technique according to the manufacturer's protocol.

Time frame: Baseline, after 12 weeks, after 24 weeks

Numbers of participants with treatment-related adverse events

The adverse events in each group will be observed and documented during the whole procedure to show the safety of the treatment.

Time frame: Baseline, after 12 weeks, after 24 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.